Eurocan is focussed on becoming a global leader in the production of high quality, legally approved
cannabis products and extracts for medical use in a range of formulations

With innovation at our core, as rapid changes in legislation are opening up the European market, we are at the forefront of the fast growing legalised medicinal cannabis industry.

Governments across Europe are quickly responding to scientific research on the health benefits of legalised medicinal cannabis products.

According to analysis of current trends, Europe is set to become the world’s largest legal cannabis market over the next five years.

Eurocan's corporate strategy is aligned with projections of this growth and is pitched to become a global leader in the production of high quality, legally approved cannabis products for medical use.


Expected growth

in legal cannabis spend (2019)


Corporate Strategy

Eurocan-map 2

Operational Strategy

Corporate strategy

Grow value for all stakeholders

Complete licensing and application processes

Supplement board and advisory board

Construct world class operational facilities

Produce high quality products and sell through off take agreements

Take opportunity of the developing European market

Operational strategy

Operational strategy

  • Vertically integrated, operationally segmented supply chain
  • Northern and southern hemisphere growing operations will maximise yields and support consistent year-round yields harvests
  • European market access for sales through EU operational hubs



Growing licence acquired Q2 2019; ground breaking commenced Q4 2019; construction to commence Q1 2020; growing to commence in 2020.


AICEP approval obtained; 23ha land secured; INFARMED application submitted.